Combinatorial oligonucleotide PCR

• US 7,115,370 B2
• Filed: 06/05/2002
• Issued: 10/03/2006
• Est. Priority Date: 06/05/2002
• Status: Expired due to Fees

• Current Assignee: Capital Genomix, Inc.
• Original Assignee: Capital Genomix, Inc.
• Inventors: Heiland, Teri, Carey, Indira, Ray, Jill M.
• Primary Examiner(s): FREDMAN, JEFFREY NORMAN
• Application Number:
  US10/164,103
• Publication Number:
  US 20060172289A1
• Time in Patent Office: 1,581 Days
• Field of Search: 435/6, 435/91.2, 435/180, 435/172.3, 435/91.1, 435/183, 531/23.1, 531/24.3, 536/24.3, 536/25.3, 536/24.33, 536/23.1, 536/24.1
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6855 Ligating adaptors
• CPC Class Codes: C12Q 2521/113 Telomerase
• CPC Class Codes: C12Q 2521/319 Exonuclease
• CPC Class Codes: C12Q 2525/119 incorporating abasic sites
• CPC Class Codes: C12Q 2531/113 PCR

Abstract

The present invention is directed to a method of detecting gene expression and analysis of both known and unknown genes. In the method utilizing combinatorial oligonucleotide PCR™, no single molecular species of DNA gives rise to more than one fragment in a collection of products which are subsequently amplified and representative of each expressed gene. More specifically, the present invention improves known methods by eliminating the recovery of restriction fragments with two identical ends and furthermore regards amplification and isolation of the restriction fragment utilizing a labeled primer.

Claims

1. A method, comprising:

a) obtaining a DNA attached to an anchor;

b) cleaving said DNA with a first restriction endonuclease (“

A”

) to release restriction fragments therefrom;

c) removing said released fragments while retaining said cleaved DNA using the anchor;

d) cleaving said retained DNA with a second restriction endonuclease (“

B”

) different from said first endonuclease, wherein said cleaving results in releasing a fragment mixture comprising;

i) A/B fragments having nonidentical A and B restriction sites on opposing ends; and

ii) B/B fragments having the same B restriction sites on opposing ends; and

e) separating said A/B fragments from said B/B fragments by a method that comprises;

i) ligating said fragment mixture with A linkers recognizing and binding said A restriction site and B linkers recognizing and binding said B restriction sites, wherein said A linkers are attached to an anchor, and said B linkers are not attached to such an anchor;

ii) retaining said A/B fragments by immobilizing fragments using the anchor on the A linkers; and

iii) discarding fragments that have not been immobilized.

2. The method of claim 1, wherein retaining the A/B fragments comprises isolating said fragments.

3. The method of claim 1, wherein retaining the A/B fragments is defined as binding the A/B fragments to a bead.

4. The method of claim 3, wherein said anchor is biotin and wherein said bead is coated with streptavidin.

5. The method of claim 1, wherein said DNA is immobilized using said anchor.

6. The method of claim 5, wherein said DNA is immobilized on a magnetic bead.

7. The method of claim 5, wherein said DNA is immobilized on a magnetic bead through a biotin label, wherein the bead further comprises a coating of streptavidin.

8. The method of claim 1, wherein the ligation of A linkers and B linkers occur concomitantly.

9. The method of claim 1, further comprising amplifying sequences from said A/B fragments.

10. The method of claim 9, wherein said amplification is by polymerase chain reaction with two different primers, one of said primers being complementary to a sequence in the A primer and one being complementary to a sequence in the B primer.

11. The method of claim 1, wherein said DNA is non-genomic DNA.

12. The method of claim 1, wherein said DNA is cDNA.

13. The method of claim 1, wherein said DNA is immobilized at the 3′

end.

14. The method of claim 12, wherein said cDNA is reverse transcribed from messenger RNA.

15. The method of claim 14, wherein said reverse transcription is initiated at an oligo dT.

16. The method of claim 14, wherein said reverse transcription is initiated at a random hexamer.

17. The method of claim 15, wherein said oligo dT is biotinylated.

18. The method of claim 9, wherein amplification is carried out with a primer set comprising:

a) a first amplification primer, wherein the 5′

sequence of said primer is complementary to an A linker sequence and the 3′

sequence comprises a specificity region;

b) a second amplification primer, wherein the 5′

sequence of said primer is complementary to a B linker sequence and the 3′

sequence comprises a specificity region.

19. The method of claim 9, wherein the said DNA fragment is preamplified.

20. The method of claim 18, wherein said amplification is performed with an array of combinations of alternate amplification primers.

21. The method of claim 9, further comprising identifying the amplified DNA.

22. The method of claim 21, wherein said identifying is based upon length.

23. The method of claim 21, wherein said identifying is performed by a computer program.

24. The method of claim 9, wherein said amplifying is performed in a multi-well plate.

25. The method of claim 18, wherein the specificity region of the first amplification primer is 3, 4, 5, 6, 7 or 8 base pairs long.

26. The method of claim 18, wherein the specificity region of the second amplification primer is 3, 4, 5, 6, 7 or 8 base pairs long.

27. The method of claim 1, wherein said first or second restriction endonuclease has a four base pair recognition site.

28. The method of claim 1, wherein said first or second restriction endonuclease has a recognition site of five, six, seven or eight base pairs.

29. The method of claim 27, wherein said first or second restriction endonuclease is NlaIII, DpnII, Sau3AI Hsp92II, MboI, NdeII, Bsp1431, Tsp509 I, HhaI, HinP1I, HpaII, MspI, Taqalphal, MaeII or K2091.

30. The method of claim 9, wherein a label is incorporated into said amplified DNA.

31. The method of claim 30, wherein said label is incorporated by means of a labeled primer.

32. The method of claim 31, further comprising partial nucleotide sequence identification of the amplified products by the identity of the label.

33. The method of claim 32, wherein said label is a chromophore.

34. The method of claim 32, wherein said label is a fluorophore.

35. The method of claim 32, wherein said label is an affinity label.

36. The method of claim 32, wherein said label is a dye.

37. The method of claim 32, wherein the 5′

end of said primer comprises an amino moiety and a fluorophore which is covalently attached by the reaction of a succinimido ester of the fluorophore to the 5′

amino-modified primer.

38. The method of claim 34, wherein said fluorophore is Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, Fluorescein, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, TAMRA, TET, Tetramethylrhodamine, or Texas Red.

39. The method of claim 9, wherein the products of said amplification are analyzed.

40. The method of claim 39, wherein said analysis of amplification products is by polyacrylamide gel electrophoresis.

41. The method of claim 39, wherein said analysis of amplification products is by capillary gel electrophoresis.

42. The method of claim 39, wherein said analysis of amplification products is by mass spectrophotometry.

43. The method of claim 39, wherein said analysis of amplification products is by energy transfer.

44. The method of claim 39, wherein said analysis of amplification products is by optical immunoassay technology.

45. The method of claim 39, wherein said analysis of amplification products utilizes fluorescently-labeled latex beads.

46. The method of claim 39, wherein said analysis of amplification products comprises quantifying amplification products.

47. The method of claim 46, wherein said quantifying is by measuring the ratio of each amplified product to a co-amplified reference-gene.

48. The method of claim 46, wherein said quantifying is by measuring the ratio of each amplified product to a panel of co-amplified reference-genes.

49. The method of claim 39, wherein said analysis of amplification products is by Real-Time PCR™

(polymerase chain reaction).

50. The method of claim 39, wherein said analysis of amplification products is performed in a multi-well plate.

51. The method of claim 39, wherein said analysis of amplification products is performed on a membrane.

52. The method of claim 39, wherein said analysis of amplification products is performed on a solid matrix.

53. The method of claim 52, wherein said solid matrix is a DNA chip.

54. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a different cell or tissue.

55. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cancerous cell or tissue.

56. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a pharmaceutical compound.

57. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a teratogenic compound.

58. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a carcinogenic compound.

59. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a toxic compound.

60. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a biological response modifier.

61. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a hormone, a hormone agonist or a hormone antagonist.

62. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a cytokine.

63. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a growth factor.

64. The method of claim 1, performed on DNA derived from a normal cell or tissue and on the DNA derived from a cell or tissue treated with the ligand of a known biological receptor.

65. The method of claim 1, performed on DNA derived from a cell or tissue type obtained from a different species.

66. The method of claim 1, performed on DNA derived from a cell or tissue type obtained from a different organism.

67. The method of claim 1, performed on DNA derived from a cell or tissue at different stages of development.

68. The method of claim 1, performed on DNA derived from a normal cell or tissue and on the DNA derived from a cell or tissue that is diseased.

69. The method of claim 1, performed on DNA derived from a cell or tissue cultured in vitro under different conditions.

70. The method of claim 1, performed on the DNA derived from a cell or tissue from two organisms of the same species with a known genetic difference.